» Articles » PMID: 35706790

Identification of Hub Genes Associated with Bladder Cancer Using Bioinformatic Analyses

Overview
Specialty Oncology
Date 2022 Jun 16
PMID 35706790
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Bladder cancer (BLCA) is the ninth most common cancer worldwide, with high mortality and recurrence rates. Studies have increasingly reported that molecular diagnosis contributes to the early diagnosis and prognostic assessment of diseases. Thus, this study aims to find new biomarkers for the diagnosis and prognosis of BLCA.

Methods: The microarray datasets GSE147983 and The Cancer Genome Atlas (TCGA)-BLCA mRNA were obtained from the Gene Expression Omnibus (GEO) and TCGA. Differentially expressed genes (DEGs) were screened using the R "Limma" package. The "ClusterProfiler" package was used to conduct Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the DEGs. A DEG protein-protein interaction (PPI) network was constructed using the Search Tool for the Retrieval of Interacting Genes (STRING) database and visualized using Cytoscape. The functional module was reanalyzed using Cytoscape's Molecular Complex Detection ("MCODE") plugin, and key genes related to BLCA were identified via the "cytoHubba" plugin. Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and the Tumor Immune Estimation Resource (TIMER) were used to verify the correlation between hub gene expression and immunity. A survival analysis of hub genes was performed using the Kaplan-Meier Plotter online tool.

Results: A total of 355 DEGs were screened out, including 236 upregulated and 119 downregulated DEGs. Some of the GO terms and pathways, such as chromosome separation, cell cycle, and cell senescence, were found to be significantly enriched in the DEGs. The key genes were kinesin family member 11 (), DLG associated protein 5 (), non-SMC condensin I complex subunit G (), cell division cycle 20 (), cyclin B2 (), BUB1 mitotic checkpoint serine (), TPX2 microtubule nucleation factor (), NUF2 component of NDC80 kinetochore complex (), kinesin family member 2C (), and cyclin B1 (). Nine of them were immune-related, including , and . Survival analysis showed that the overexpression of BUB1B, CCNB1, CDC20, and DLGAP5 significantly reduced overall survival (OS) in patients with BLCA.

Conclusions: This study provided a theoretical basis for elucidating the pathogenesis and evaluating the prognosis of BLCA by screening potential biomarkers of BLCA.

Citing Articles

Activation of the Anaphase Promoting Complex Restores Impaired Mitotic Progression and Chemosensitivity in Multiple Drug-Resistant Human Breast Cancer.

Lubachowski M, VanGenderen C, Valentine S, Belak Z, Davies G, Arnason T Cancers (Basel). 2024; 16(9).

PMID: 38730707 PMC: 11083742. DOI: 10.3390/cancers16091755.


Comprehensive analysis of IGF2BP3 with expression features, prognosis, immune modulation and stemness in hepatocellular carcinoma and pan-cancer.

Qin S, Jin H, Li Y, Chen X, He J, Xiao J J Cancer. 2024; 15(9):2845-2865.

PMID: 38577615 PMC: 10988304. DOI: 10.7150/jca.92768.


KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker.

Kreis N, Moon H, Wordeman L, Louwen F, Solbach C, Yuan J Crit Rev Clin Lab Sci. 2024; 61(6):404-434.

PMID: 38344808 PMC: 11815995. DOI: 10.1080/10408363.2024.2309933.


DLGAP5 triggers proliferation and metastasis of bladder cancer by stabilizing E2F1 via USP11.

Zhou F, Deng Z, Shen D, Lu M, Li M, Yu J Oncogene. 2024; 43(8):594-607.

PMID: 38182895 DOI: 10.1038/s41388-023-02932-y.

References
1.
Li Z, Yu B, Qi F, Li F . KIF11 Serves as an Independent Prognostic Factor and Therapeutic Target for Patients With Lung Adenocarcinoma. Front Oncol. 2021; 11:670218. PMC: 8103954. DOI: 10.3389/fonc.2021.670218. View

2.
Sugeeta S, Sharma A, Ng K, Nayak A, Vasdev N . Biomarkers in Bladder Cancer Surveillance. Front Surg. 2021; 8:735868. PMC: 8506024. DOI: 10.3389/fsurg.2021.735868. View

3.
Tan W, Tan W, Tan M, Khetrapal P, Dong L, deWinter P . Novel urinary biomarkers for the detection of bladder cancer: A systematic review. Cancer Treat Rev. 2018; 69:39-52. DOI: 10.1016/j.ctrv.2018.05.012. View

4.
Lei C, Wang W, Zhu Y, Fang W, Tan W . The decrease of cyclin B2 expression inhibits invasion and metastasis of bladder cancer. Urol Oncol. 2015; 34(5):237.e1-10. DOI: 10.1016/j.urolonc.2015.11.011. View

5.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View